Health Care·Pharmaceuticals·$9.5B
Axsome Therapeutics (AXSM) is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $10 billion, its advancements in this critical sector could significantly impact patient care and treatment options.
EPS
Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
50%
Avg EPS Surprise
-12.47%
Avg Stock Reaction
+1.25%
In Q4 2025, Axsome reported an EPS of $-0.56, outperforming expectations by 20.34%. However, the stock fell by nearly 5% the following day, indicating mixed investor sentiment.
Management Promises & Guidance
Analysts expect Axsome to report a loss of $-0.76 per share with revenues around $192 million. This reflects cautious optimism as the company continues to develop its pipeline.
Bull Case
If Axsome beats EPS estimates and reports strong revenue growth, it could signal robust demand for its products, potentially boosting investor confidence.
Bear Case
Conversely, if the company misses on both EPS and revenue, it may raise concerns about its growth trajectory and market competitiveness.
EPS
$-0.76Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.
Revenue
$192MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Axsome achieve revenue of at least $192 million this quarter?
Meeting or exceeding this revenue target could indicate strong market demand and validate the company's growth strategy.
Q2
What specific progress has been made in clinical trials for key therapies?
Updates on clinical trials can significantly influence investor sentiment and expectations for future product launches.
Why consensus could be wrong
The Street may be underestimating the potential for Axsome to exceed revenue expectations due to strong demand for its therapies, which could lead to a more favorable EPS outcome than anticipated.
Supporting Evidence
Recent trends in the pharmaceutical sector indicate a growing market for CNS therapies.
Axsome's recent clinical trial results have shown promising efficacy, suggesting potential for higher sales.
The company has been actively expanding its market presence, which may not be fully reflected in current estimates.
Key Risk
If revenue comes in below $164 million, it could undermine the bullish narrative and lead to a reevaluation of growth prospects.
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized as it reflects the company's ability to execute its growth strategy amid competitive pressures.
Bull Confirmed If
Reporting an EPS loss narrower than $-0.76 and revenue exceeding $192 million would confirm the bull case.
Bear Confirmed If
An EPS loss wider than $-0.76 and revenue below $164 million would support the bear case.
Implied Move
±4.2%
The options market is pricing in a moderate move around the earnings report, suggesting uncertainty about the results.
Cross-company pattern from 30 similar setups.
Prior-quarter beat in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.9%, with a raw directional average of +2.3% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Axsome beats earnings expectations, history suggests a potential stock increase of around +2.93%, confirming positive market sentiment.
In-Line / Cautious
An in-line report could lead to muted reactions, as management commentary may drive the stock's movement in either direction.
Miss
If the company misses expectations, history indicates a potential decline of around -0.42%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COLGATE PALMOLIVE CO
May 1, 2026